The use of digital health tools in the management of inflammatory bowel disease: a systematic review.

Minerva Gastroenterol (Torino)Sep 1, 2026
Clinical ResearchGastroenterology

Giorgia Meddi, Camilla Mencaroni, Elisa Schiavoni et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the use of digital health tools (DHTs) in managing inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The review analyzed 15 articles to assess the characteristics and usability of these tools. The findings suggest that while DHTs show promise in improving disease management, they need further refinement to meet specific population needs.

Key findings

  • Fifteen articles were analyzed regarding digital health tools for IBD management.
  • DHTs have potential to enhance clinical and self-management of IBD.
  • Current DHTs require further refinement for better adaptation to patient needs.

Why it matters

The integration of digital health tools in IBD management could enhance patient monitoring and timely interventions, potentially improving patient outcomes and quality of life. Understanding their effectiveness is crucial for optimizing care strategies.

Source

PubMed · PMID 42670816

Published in Minerva Gastroenterol (Torino). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.